专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08178513B2 Heterocyclic aspartyl protease inhibitors 有权
标题翻译：杂环天门冬氨酰蛋白酶抑制剂
公开(公告)号：US08178513B2
公开(公告)日：2012-05-15
申请号：US12480391
申请日：2009-06-08
申请人： Zhaoning Zhu , Brian McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey O. Strickland , Elizabeth M. Smith , Andrew W. Stamford , William J. Greenlee , Robert D. Mazzola, Jr. , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X. H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter
发明人： Zhaoning Zhu , Brian McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey O. Strickland , Elizabeth M. Smith , Andrew W. Stamford , William J. Greenlee , Robert D. Mazzola, Jr. , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X. H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter
IPC分类号： A01N57/00 , A01N43/54 , A01N43/40 , A61K31/675 , A61K31/44 , A61K31/445 , C07D239/02 , C07D233/00 , C07D239/24 , C07D401/00
CPC分类号： C07D233/88 , A61K31/4168 , A61K31/4178 , A61K31/4184 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/5377 , A61K31/655 , A61K45/06 , C07D233/46 , C07D233/70 , C07D235/02 , C07D239/22 , C07D239/70 , C07D271/07 , C07D273/00 , C07D295/15 , C07D401/04 , C07D401/06 , C07D401/08 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/10 , C07D403/12 , C07D405/06 , C07D405/10 , C07D405/14 , C07D407/06 , C07D409/04 , C07D409/06 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/06 , Y02A50/411
摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, U, X, R1, R2, R3, and R4 are as defined herein, and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of using such compounds to inhibit aspartyl protease and to treat a variety of disease or disorders, including cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist
摘要翻译：公开了式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂化物，其中W，U，X，R 1，R 2，R 3和R 4如本文所定义，并且药物组合物包含式I化合物还公开了使用这些化合物抑制天冬氨酰蛋白酶和治疗各种疾病或病症（包括心血管疾病，认知和神经变性疾病）的方法。还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱拮抗剂组合治疗认知或神经变性疾病的方法

2. 发明授权

US08168641B2 Aspartyl protease inhibitors 有权
标题翻译：天冬氨酰蛋白酶抑制剂
公开(公告)号：US08168641B2
公开(公告)日：2012-05-01
申请号：US11759336
申请日：2007-06-07
申请人： Yusheng Wu , Ulrich Iserloh , Jared N. Cumming , Xiaoxiang Liu , Robert D. Mazzola , Zhong-Yue Sun , Ying Huang , Andrew Stamford , Brian McKittrick , Zhaoning Zhu
发明人： Yusheng Wu , Ulrich Iserloh , Jared N. Cumming , Xiaoxiang Liu , Robert D. Mazzola , Zhong-Yue Sun , Ying Huang , Andrew Stamford , Brian McKittrick , Zhaoning Zhu
IPC分类号： C07D239/20 , C07D239/22 , A61K31/497 , A61K31/513 , A61K31/506 , A61P9/00 , A61P25/28 , A61P31/18 , C07D495/20 , A61K31/527
CPC分类号： C07D239/20 , C07D401/04 , C07D401/10 , C07D403/04 , C07D405/04 , C07D409/14 , C07D411/04 , C07D417/04 , C07D417/14 , C07D495/20
摘要： Disclosed are compounds of formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R1, R2, R6, R7, R30 and R31 are as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
摘要翻译：公开了式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂合物，U，W，X，R 1，R 2，R 6，R 7，R 30和R 31如上文在说明书中所述。还公开了抑制天冬氨酰蛋白酶的方法，特别是治疗心血管疾病，认知和神经变性疾病的方法。还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱m1激动剂或m2拮抗剂组合治疗认知或神经变性疾病的方法。

3. 发明申请

US20110009392A1 GAMMA SECRETASE MODULATORS 审中-公开
公开(公告)号：US20110009392A1
公开(公告)日：2011-01-13
申请号：US12671806
申请日：2008-08-04
申请人： Zhaoning Zhu , William J. Greenlee , John P. Caldwell , Robert D. Mazzola, JR. , Brian McKittrick , Chad E. Bennett , Xianhai Huang , Hubert B. Josien , Duane A. Burnett
发明人： Zhaoning Zhu , William J. Greenlee , John P. Caldwell , Robert D. Mazzola, JR. , Brian McKittrick , Chad E. Bennett , Xianhai Huang , Hubert B. Josien , Duane A. Burnett
IPC分类号： A61K31/55 , C07D487/04 , C07D235/02 , C07D498/04 , C07D491/04 , A61K31/4188 , A61K31/519 , A61K31/535 , A61K31/4353 , A61K31/435 , A61K31/47 , A61K31/505 , A61K31/397 , A61K31/4406 , A61K38/16 , A61P25/28
CPC分类号： C07D487/04 , C07D217/24 , C07D498/04
摘要： In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

4. 发明申请

US20090306047A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS 有权
标题翻译：异源ASPARTYL蛋白酶抑制剂
公开(公告)号：US20090306047A1
公开(公告)日：2009-12-10
申请号：US12480391
申请日：2009-06-08
申请人： Zhaoning Zhu , Brian McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey Strickland , Elizabeth M. Smith , Andrew Stamford , William J. Greenlee , Robert Mazzola , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X.H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter
发明人： Zhaoning Zhu , Brian McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey Strickland , Elizabeth M. Smith , Andrew Stamford , William J. Greenlee , Robert Mazzola , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X.H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter
IPC分类号： A61K31/4178 , C07D403/10 , C07D233/88 , C07D401/14 , A61K31/4168 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/435 , A61K31/4353 , A61K31/55 , A61P25/28
CPC分类号： C07D233/88 , A61K31/4168 , A61K31/4178 , A61K31/4184 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/5377 , A61K31/655 , A61K45/06 , C07D233/46 , C07D233/70 , C07D235/02 , C07D239/22 , C07D239/70 , C07D271/07 , C07D273/00 , C07D295/15 , C07D401/04 , C07D401/06 , C07D401/08 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/10 , C07D403/12 , C07D405/06 , C07D405/10 , C07D405/14 , C07D407/06 , C07D409/04 , C07D409/06 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/06 , Y02A50/411
摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(═O)— or —C(═NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(═NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.
摘要翻译：公开了式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂化物，其中W是键，-C（-S） - ， - S（O） - ， - S（O） -C（ - ） - ， - O - ， - C（R6）（R7） - ， - N（R5） - 或-C（-N（R5） X是-O - ， - N（R 5） - 或-C（R 6）（R 7） - ; 条件是当X是-O-时，U不是-O-，-S（O） - ， - S（O）2 - ， - C（-O） - 或-C（-NR 5） - ; U是一个键，-S（O） - ， - S（O）2 - ， - C（O） - ， - O - ， - （O）（OR 15） - ， - （C（R6）（R7））b-或-N（R5） - ; 其中b为1或2; 条件是当W是-S（O） - ， - S（O）2 - ， - O-或-N（R 5） - 时，U不是-S（O） - ， - S（O） -O-或-N（R 5） - ; 条件是当X为-N（R5） - 且W为-S（O） - ， - S（O）2 - ， - O-或-N（R5） - 时，则U不为键; 并且R1，R2，R3，R4，R5，R6和R7如说明书中所定义; 以及包含式I化合物的药物组合物。还公开了抑制天冬氨酰蛋白酶的方法，特别是治疗心血管疾病，认知和神经变性疾病的方法以及抑制人类免疫缺陷病毒，plasmepins，组织蛋白酶D 和原生动物酶。还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱拮抗剂组合来治疗认知或神经变性疾病的方法。

5. 发明授权

US07592419B2 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease 失效
标题翻译：丙型肝炎病毒NS3-丝氨酸蛋白酶的大环抑制剂
公开(公告)号：US07592419B2
公开(公告)日：2009-09-22
申请号：US10948367
申请日：2004-09-23
申请人： Srikanth Venkatraman , F. George Njoroge , Wanli Wu , Viyyoor M. Girijavallabhan , Brian McKittrick , Jing Su , Francisco Velazquez , Patrick A. Pinto
发明人： Srikanth Venkatraman , F. George Njoroge , Wanli Wu , Viyyoor M. Girijavallabhan , Brian McKittrick , Jing Su , Francisco Velazquez , Patrick A. Pinto
IPC分类号： A61K38/12 , A61K38/00
CPC分类号： C07D245/04 , A61K31/33 , A61K38/12 , A61K38/21 , A61K38/212 , C04B35/632 , C07D401/12 , C07D403/12 , C07D409/12 , C07D487/04 , C07D513/04 , C07K5/0217 , C07K5/0802 , A61K2300/00
摘要： The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula 1: wherein Z′, L′, M′, R1, X and D are defined herein.
摘要翻译：本发明公开了具有HCV蛋白酶抑制活性的新化合物以及包含这些化合物的药物组合物及其用于治疗与HCV蛋白酶相关的病症的方法。新化合物通常包括15-20个成员大环，并且具有结构式1的一般结构：其中Z'，L'，M'，R 1，X和D在本文中定义。

6. 发明授权

US07592348B2 Heterocyclic aspartyl protease inhibitors 有权
标题翻译：杂环天门冬氨酰蛋白酶抑制剂
公开(公告)号：US07592348B2
公开(公告)日：2009-09-22
申请号：US11010772
申请日：2004-12-13
申请人： Zhaoning Zhu , Brian McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey Strickland , Elizabeth M. Smith , Andrew Stamford , William J. Greenlee , Robert Mazzola , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X. H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter
发明人： Zhaoning Zhu , Brian McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey Strickland , Elizabeth M. Smith , Andrew Stamford , William J. Greenlee , Robert Mazzola , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X. H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter
IPC分类号： A61K31/505 , C07D239/02
CPC分类号： C07D233/88 , A61K31/4168 , A61K31/4178 , A61K31/4184 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/5377 , A61K31/655 , A61K45/06 , C07D233/46 , C07D233/70 , C07D235/02 , C07D239/22 , C07D239/70 , C07D271/07 , C07D273/00 , C07D295/15 , C07D401/04 , C07D401/06 , C07D401/08 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/10 , C07D403/12 , C07D405/06 , C07D405/10 , C07D405/14 , C07D407/06 , C07D409/04 , C07D409/06 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/06 , Y02A50/411
摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(═O)— or —C(═NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(═NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.
摘要翻译：公开了式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂化物，其中W是键，-C（-S） - ， - S（O） - ， - S（O） -C（ - ） - ， - O - ， - C（R6）（R7） - ， - N（R5） - 或-C（-N（R5） X是-O - ， - N（R 5） - 或-C（R 6）（R 7） - ; 条件是当X是-O-时，U不是-O-，-S（O） - ， - S（O）2 - ， - C（-O） - 或-C（-NR 5） - ; U是一个键，-S（O） - ， - S（O）2 - ， - C（O） - ， - O - ， - （O）（OR 15） - ， - （C（R6）（R7））b-或-N（R5） - ; 其中b为1或2; 条件是当W是-S（O） - ， - S（O）2 - ， - O-或-N（R 5） - 时，U不是-S（O） - ， - S（O） -O-或-N（R 5） - ; 条件是当X为-N（R5） - 且W为-S（O） - ， - S（O）2 - ， - O-或-N（R5） - 时，则U不为键; 并且R1，R2，R3，R4，R5，R6和R7如说明书中所定义; 以及包含式I化合物的药物组合物。还公开了抑制天冬氨酰蛋白酶的方法，特别是治疗心血管疾病，认知和神经变性疾病的方法以及抑制人类免疫缺陷病毒，plasmepins，组织蛋白酶D 和原生动物酶。还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱拮抗剂组合来治疗认知或神经变性疾病的方法。

7. 发明授权

US07560451B2 Aspartyl protease inhibitors 失效
标题翻译：天冬氨酰蛋白酶抑制剂
公开(公告)号：US07560451B2
公开(公告)日：2009-07-14
申请号：US11589387
申请日：2006-10-30
申请人： Zhaoning Zhu , Andrew W. Stamford , Brian McKittrick
发明人： Zhaoning Zhu , Andrew W. Stamford , Brian McKittrick
IPC分类号： C07D411/04 , A61K31/553
CPC分类号： C07D413/04 , C07F9/65848
摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.
摘要翻译：公开了式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂合物，其中W，R 1，R 2，R 3，R 4，R 5，R 6和R 7如说明书中所定义; 以及包含式I化合物的药物组合物。还公开了抑制天冬氨酰蛋白酶的方法，特别是治疗心血管疾病，认知和神经变性疾病的方法以及抑制人类免疫缺陷病毒，plasmepins，组织蛋白酶D 和原生动物酶。还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱拮抗剂组合来治疗认知或神经变性疾病的方法。

8. 发明申请

US20080076751A1 Azetidinone Derivatives and Methods of Use Thereof 失效
标题翻译：氮杂环丁酮衍生物及其使用方法
公开(公告)号：US20080076751A1
公开(公告)日：2008-03-27
申请号：US11854754
申请日：2007-09-13
申请人： Robert Aslanian , Chad Bennett , Duane Burnett , Tin-Yau Chan , Eugenia Kiselgof , Chad Knutson , Joel Harris , Brian McKittrick , Anandan Palani , Elizabeth Smith , Henry Vaccaro , Dong Xiao , Hyunjin Kim
发明人： Robert Aslanian , Chad Bennett , Duane Burnett , Tin-Yau Chan , Eugenia Kiselgof , Chad Knutson , Joel Harris , Brian McKittrick , Anandan Palani , Elizabeth Smith , Henry Vaccaro , Dong Xiao , Hyunjin Kim
IPC分类号： A61K31/397 , A61P25/04 , A61P3/00 , C07D471/10
CPC分类号： C07D471/10
摘要： The present invention relates to Azetidinone Derivatives, compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.
摘要翻译：本发明涉及氮杂环丁酮衍生物，包含氮杂环丁酮衍生物的组合物和用于治疗或预防脂质代谢紊乱，疼痛，糖尿病，血管病症，脱髓鞘或非酒精性脂肪性肝病的方法，包括向患者施用有效量的氮杂环丁酮衍生物。

9. 发明申请

US20080070889A1 AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM 失效
标题翻译： AZETIDINE和AZETIDONE衍生物有助于治疗脂肪代谢的疼痛和疾病
公开(公告)号：US20080070889A1
公开(公告)日：2008-03-20
申请号：US11854711
申请日：2007-09-13
申请人： DUANE BURNETT , Brian McKittrick
发明人： DUANE BURNETT , Brian McKittrick
IPC分类号： C07D487/10 , A61K31/397 , A61P3/00
CPC分类号： C07D487/10
摘要： Disclosed are compounds of the formula wherein Z1 is —CH2— or —C(O)—, R4 and R5 are carbon chains (and optionally, together can form a C2 bridge), u and v are independently an integer of 0-3 such that there sum is from 3 to 5, and R2 is heteroaryl, and R1 and R3 are as defined herein. Also disclosed are methods of treating pain, and methods of inhibiting the absorption of cholesterol using a compound of formula I.
摘要翻译：公开了下式的化合物其中Z 1是-CH 2 - 或-C（O） - ，R 4和R 4， 5是碳链（并且可选地，一起可以形成C 2 H 2桥），u和v独立地是0-3的整数，使得总和为3至5，并且 R 2是杂芳基，R 1和R 3如本文所定义。还公开了治疗疼痛的方法，以及使用式I化合物抑制胆固醇吸收的方法。

10. 发明申请

US20080019978A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 有权
标题翻译：含氮杂环化合物及其使用方法
公开(公告)号：US20080019978A1
公开(公告)日：2008-01-24
申请号：US11771538
申请日：2007-06-29
申请人： Anandan Palani , Jing Su , Dong Xiao , Xianhai Huang , Ashwin Rao , Xiao Chen , Haiqun Tang , Jun Qin , Ying Huang , Robert Aslanian , Brian McKittrick , Sylvia Degrado
发明人： Anandan Palani , Jing Su , Dong Xiao , Xianhai Huang , Ashwin Rao , Xiao Chen , Haiqun Tang , Jun Qin , Ying Huang , Robert Aslanian , Brian McKittrick , Sylvia Degrado
IPC分类号： A61K31/519 , A61K31/397 , A61K31/56 , A61K31/60 , A61K38/16 , A61K39/395 , A61P1/00 , A61P11/00 , A61P3/00 , A61P3/10 , A61P35/00 , A61P9/00 , C07D239/70
CPC分类号： C07D491/04 , C07D471/04
摘要： The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
摘要翻译：本发明提供式（I）的化合物及其药学上可接受的盐，溶剂合物，酯和互变异构体，其中：Q选自：和L选自：药物组合物，其包含一种或多种更多的式（I）化合物和使用式（I）化合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式